SCHEMBL2574751

SCHEMBL2574751

FC1(F)CCN([C@H]2CCNC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.47
HRH3 Q9Y5N1 1/20 0.34
IL1B P01584 1/20 0.31
P2RX7 Q99572 1/20 0.31
KHK P50053 1/20 0.30
CYP2D6 P10635 1/20 0.30
AXL P30530 1/20 0.30
CSNK1D P48730 1/20 0.30
MERTK Q12866 1/20 0.30
ARG1 P05089 1/20 0.30
ARG2 P78540 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15363252 1.00 HTR6 (0.47) HTR6HRH3IL1BP2RX7KHK
SCHEMBL521969 0.88 HRH3 (0.39) HTR6HRH3
4,4-Difluoro-Piperidinium SCHEMBL14655229 0.84 HRH3 (0.37) HTR6HRH3
SCHEMBL2272753 0.83 HTR6 (0.34) HTR6HRH3
Hydrochloric Acid SCHEMBL31115119 0.81 HRH3 (0.33) HTR6HRH3
SCHEMBL24912034 0.78 HTR6 (0.46) HTR6
SCHEMBL4297941 0.78 HTR6 (0.46) HTR6KHKARG1ARG2
SCHEMBL20522872 0.78 HTR6 (0.46) HTR6
SCHEMBL4297939 0.78 HTR6 (0.46) HTR6KHKARG1ARG2
SCHEMBL15363274 0.77 HTR6 (0.52) HTR6KHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018383-B1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS PFIZER PROD INC (US) 2011-11-09 EP disclosed
EP-2018383-B1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS PFIZER PROD INC (US) 2011-11-09 EP disclosed
US-7732604-B2 Triazolopyrazine derivatives PFIZER INC. (US) 2010-06-08 US disclosed
US-7732604-B2 Triazolopyrazine derivatives PFIZER INC. (US) 2010-06-08 US disclosed
US-7732604-B2 Triazolopyrazine derivatives PFIZER INC. (US) 2010-06-08 US disclosed
US-20100105656-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2010-04-29 US disclosed
US-20100105656-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2010-04-29 US disclosed
US-20100105656-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2010-04-29 US disclosed
EP-2018383-A1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS Pfizer Products Inc. (US) 2009-01-28 EP disclosed
WO-2007132308-A1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS PFIZER PRODUCTS INC. (US) 2007-11-22 WO disclosed
WO-2007132308-A1 TRIAZOLOPYRAZINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS PFIZER PRODUCTS INC. (US) 2007-11-22 WO disclosed
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2007-11-15 US disclosed
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2007-11-15 US disclosed
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES PFIZER INC. 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265272-A1 TRIAZOLOPYRAZINE DERIVATIVES JAK2, ABL1, CCND2 HTR6 4065/4885HRH3 155/4885IL1B 2697/4885
US-20100105656-A1 TRIAZOLOPYRAZINE DERIVATIVES JAK2, ABL1, CCND2 HTR6 4065/4885HRH3 155/4885IL1B 2697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.